Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi's sarcoma

Francesca Cainelli, Alfredo Vallone

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Kaposi's sarcoma is a vascular tumor linked to the presence of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) and the incidence of which has increased considerably the world over after the onset of the human immunodeficiency virus (HIV) pandemic. Antiretroviral therapy combined with cytotoxic agents has been established as the treatment of choice in the past 10 years. Among chemotherapeutic agents, pegylated liposomal doxorubicin has become the preferred one for patients with HIV-associated Kaposi's sarcoma in Western countries. The drug in this formulation localizes better to the tumor and has higher efficacy. Skin toxicity, mucositis, and leukopenia/neutropenia are the main side effects. Hepatotoxicity and mild cardiotoxicity are observed less frequently. Pegylated liposomal doxorubicin impacts favorably on quality of life. Although cost effective in Western countries, the drug is less so in developing countries.

Original languageEnglish
Pages (from-to)385-390
Number of pages6
JournalBiologics: Targets and Therapy
Volume3
DOIs
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Human Herpesvirus 8
Kaposi's Sarcoma
HIV
Safety
Drug Compounding
Mucositis
Cytotoxins
Leukopenia
Pandemics
Neutropenia
Developing Countries
Blood Vessels
Neoplasms
Quality of Life
Costs and Cost Analysis
Skin
Incidence
Therapeutics
Pharmaceutical Preparations
liposomal doxorubicin

Keywords

  • HIV infection
  • Kaposi's sarcoma
  • Pegylated liposomal doxorubicin

ASJC Scopus subject areas

  • Oncology
  • Immunology and Allergy
  • Pharmacology (medical)
  • Gastroenterology
  • Rheumatology

Cite this

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi's sarcoma. / Cainelli, Francesca; Vallone, Alfredo.

In: Biologics: Targets and Therapy, Vol. 3, 2009, p. 385-390.

Research output: Contribution to journalReview article

@article{ee4bf5265b2b4c9c88443bfd20d60bb0,
title = "Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi's sarcoma",
abstract = "Kaposi's sarcoma is a vascular tumor linked to the presence of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) and the incidence of which has increased considerably the world over after the onset of the human immunodeficiency virus (HIV) pandemic. Antiretroviral therapy combined with cytotoxic agents has been established as the treatment of choice in the past 10 years. Among chemotherapeutic agents, pegylated liposomal doxorubicin has become the preferred one for patients with HIV-associated Kaposi's sarcoma in Western countries. The drug in this formulation localizes better to the tumor and has higher efficacy. Skin toxicity, mucositis, and leukopenia/neutropenia are the main side effects. Hepatotoxicity and mild cardiotoxicity are observed less frequently. Pegylated liposomal doxorubicin impacts favorably on quality of life. Although cost effective in Western countries, the drug is less so in developing countries.",
keywords = "HIV infection, Kaposi's sarcoma, Pegylated liposomal doxorubicin",
author = "Francesca Cainelli and Alfredo Vallone",
year = "2009",
doi = "10.2147/BTT.S3915",
language = "English",
volume = "3",
pages = "385--390",
journal = "Biologics: Targets and Therapy",
issn = "1177-5475",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi's sarcoma

AU - Cainelli, Francesca

AU - Vallone, Alfredo

PY - 2009

Y1 - 2009

N2 - Kaposi's sarcoma is a vascular tumor linked to the presence of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) and the incidence of which has increased considerably the world over after the onset of the human immunodeficiency virus (HIV) pandemic. Antiretroviral therapy combined with cytotoxic agents has been established as the treatment of choice in the past 10 years. Among chemotherapeutic agents, pegylated liposomal doxorubicin has become the preferred one for patients with HIV-associated Kaposi's sarcoma in Western countries. The drug in this formulation localizes better to the tumor and has higher efficacy. Skin toxicity, mucositis, and leukopenia/neutropenia are the main side effects. Hepatotoxicity and mild cardiotoxicity are observed less frequently. Pegylated liposomal doxorubicin impacts favorably on quality of life. Although cost effective in Western countries, the drug is less so in developing countries.

AB - Kaposi's sarcoma is a vascular tumor linked to the presence of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) and the incidence of which has increased considerably the world over after the onset of the human immunodeficiency virus (HIV) pandemic. Antiretroviral therapy combined with cytotoxic agents has been established as the treatment of choice in the past 10 years. Among chemotherapeutic agents, pegylated liposomal doxorubicin has become the preferred one for patients with HIV-associated Kaposi's sarcoma in Western countries. The drug in this formulation localizes better to the tumor and has higher efficacy. Skin toxicity, mucositis, and leukopenia/neutropenia are the main side effects. Hepatotoxicity and mild cardiotoxicity are observed less frequently. Pegylated liposomal doxorubicin impacts favorably on quality of life. Although cost effective in Western countries, the drug is less so in developing countries.

KW - HIV infection

KW - Kaposi's sarcoma

KW - Pegylated liposomal doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=77952889184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952889184&partnerID=8YFLogxK

U2 - 10.2147/BTT.S3915

DO - 10.2147/BTT.S3915

M3 - Review article

VL - 3

SP - 385

EP - 390

JO - Biologics: Targets and Therapy

JF - Biologics: Targets and Therapy

SN - 1177-5475

ER -